Nanoscope® team conferred Phase II Retinal Organoid Challenge (ROC) award by National Institute of Health
News provided by
Share this article
Share this article
BEDFORD, Texas, Feb. 2, 2021 /PRNewswire/ To meet the advance challenge for generating a physiologically relevant three-dimensional (3D) retinal organoid, Nanoscope researchers
® in collaboration with University of Colorado, and Miami University
were recently awarded the top prize from the 3D-ROC challenge by the National Institute of Health (NIH). https://www.nei.nih.gov/about/goals-and-accomplishments/nei-research-initiatives/3-d-retina-organoid-challenge-3-d-roc/2017-ideation-challenge/2017-ideation-winner-and-honorable-mention
The organoids provide a unique opportunity for evaluating novel gene therapies including Multi-Characteristic Opsin (MCO) gene therapy for vision restoration. This is an active therapeutic development area for Nanoscope Therapeutics to evaluate effectiveness of MCO optogenetic t
Nanoscope Therapeutics Receives Orphan Drug Designation for gene therapy of blindness
This is the second program based on Nanoscope s Multi-Characteristic Opsin Platform to receive orphan designation. This designation highlights the unmet need for therapy of patients with rare form of inherited macular degeneration.
News provided by
Share this article
Share this article
BEDFORD, Texas, Jan. 25, 2021 /PRNewswire/ NANOSCOPE THERAPEUTICS Inc., a clinical-stage biotechnology company determined to change lives through the ocular gene therapy, today announced that it has received an Orphan drug designation from FDA for gene therapy-based treatment of Stargardt disease, a form of inherited retinal degenerative disease caused by gene mutation and passed on to children.
The first part of the pioneering test, developed by researchers at University College London, is called DARC.
DARC involves injecting dye into a person s bloodstream to illuminate stressed endothelial cells in the retina, so they appear bright white under a fluorescent camera.
These stressed retinal cells could lead to abnormalities and later leaking blood vessels – causing AMD, which can severely compromise the central field of vision.
The second part of the test uses an AI algorithm, trained to detect whether the highlighted white spots are around the macula – which indicates high AMD risk.
The AI is more objective and consistent than the judgements of human clinicians, and it can also analyse thousands of images of the retina.